Imaging of mood- and anxiety-related disorders (IMARD)

“We want to determine the best treatment for each person by using neuroimaging”

    Mood and anxiety disorders are among the leading causes of disability. Approximately one out of four people will suffer from one of these disorders during their lifetime. And, unfortunately, the treatments available today only help half of sufferers, and it is often necessary to resort to trial and error to find the right treatment. We thus need reliable, objective, valid indicators that allow us to predict from the outset the body’s response to a treatment. Only by doing this will we be able to recommend the right treatment to each patient.

    IMARD group’s research has two goals: to identify the changes in the brain involved in mood and anxiety disorders, and to determine the brain mechanisms that predict who will respond better or worse to different treatments. To achieve these goals, the group uses different neuroimaging techniques (such as magnetic resonance imaging of the brain), which are often combined with artificial-intelligence techniques.

Last news:

Estem realitzant un estudi per a avaluar l’efectivitat d’una intervenció psicològica breu a través d’una web per a millorar el benestar emocional...
An international collaboration led by the IMARD group has published this new tool in Biological Psychiatry to understand the neuroanatomical...
This meta-analysis revealed that individuals with BD tend to exhibit longer latency to first fixation, fewer fixations, shorter gaze duration...
Our meta-analysis of 1683 RCTs (375,120 participants) in JAMA Psychiatry found significant underreporting of race and ethnicity and underrepresentation...
Lydia presented her work on the role of genetics, cognition, and comorbidities in the neural heterogeneity in mental disorders...
In this meta-analysis of 15 studies, rumination emerged as the ER strategy most strongly associated with both depressive and (hypo)manic